Valproic Acid Inhibits Chronic Toxoplasma Infection and Associated Brain Inflammation in Mice

Area of Science:

• Neuroparasitology
• Infectious Diseases
• Pharmacology

Background:

• Toxoplasma gondii infection is linked to neuropsychiatric disorders like schizophrenia.
• Valproic acid shows in vitro activity against T. gondii tachyzoites but lacks proven in vivo efficacy.
• Chronic T. gondii infection establishes persistent brain cysts and neuroinflammation.

Purpose of the Study:

• To evaluate the efficacy of valproic acid against chronic Toxoplasma gondii infection in a mouse model.
• To quantify parasite burden and neuroinflammatory markers in the brains of infected mice treated with valproic acid.
• To compare valproic acid's effects with trimethoprim-sulfamethoxazole (TMP-SMZ), a standard toxoplasmosis treatment.

Main Methods:

• Quantitative real-time PCR (qPCR) was used to measure parasite DNA (BAG1, REP529, SAG1) in mouse brains.
• Tumor necrosis factor alpha (TNF-α) expression in the brain was quantified.
• Histological analysis assessed brain cyst burden, perivascular infiltration, and glial nodules.

Main Results:

• Valproic acid significantly reduced BAG1, SAG1, and REP529 copy numbers in mouse brains (P < 0.0001).
• The drug comparably decreased brain TNF-α expression to levels seen with TMP-SMZ (P < 0.0001).
• Histological examinations revealed marked reductions in T. gondii cysts and neuroinflammation.

Conclusions:

• Valproic acid demonstrates direct efficacy against chronic Toxoplasma gondii infection in vivo.
• The findings support valproic acid as a potential therapeutic agent for chronic toxoplasmosis.
• Results may inform treatment strategies for neuropsychiatric patients and guide the development of novel anti-Toxoplasma drugs.